ASCLETIS-B (01672.HK): ASC36_35 FDC Exhibits Superior Weight-Loss Efficacy versus Eloralintide Combined with Tirzepatide; Preclinical Data to Be Presented at EASD 2026
NewTimeSpace News: Ascletis Pharma Inc. (01672.HK) announced that preclinical data of ASC36_35 FDC, a once-monthly injectable fixed-dose co-formulation of ASC36 and ASC35, has been accepted for short oral discussion at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD). Data show the candidate delivers superior weight-loss effects compared with eloralintide combined with tirzepatide in diet-induced obese (DIO) animal models.
NewTimeSpace News: On 23 July 2026, Ascletis Pharma Inc. (01672.HK) issued a voluntary announcement unveiling that preclinical data of ASC36_35 FDC will be presented at EASD 2026 Annual Meeting.
ASC36_35 FDC is a once-monthly subcutaneous fixed-dose co-formulation comprising ASC36 (peptide amylin receptor agonist) and ASC35 (peptide GLP-1R/GIPR agonist). It is expected to become a potential first-in-class drug candidate targeting three validated therapeutic targets: amylin receptor, GLP-1R and GIPR. The formulation adopts the Self-Assembling Lipid Depot (SALD) design and is developed based on Ascletis’ proprietary Ultra-Long-Acting Platform (ULAP) technology.
Preclinical results demonstrate that ASC36_35 FDC achieves better weight reduction than the combination regimen of eloralintide plus tirzepatide in diet-induced obese (DIO) animal models. Relevant data will be delivered via short oral discussion at the EASD Annual Meeting on 1 October 2026.
Dr. Wu Jinzi, Founder, Chairman and Chief Executive Officer of Ascletis, commented that he believes the co-formulation of ASC36 and ASC35 is poised to achieve superior weight-loss outcomes versus eloralintide combined with tirzepatide in obese populations.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- Lung Fung Group (02290.HK): Q2 Retail Sales Rise 21.2% YoY to HK$829.3M; Store Count Increases to 31
- CLOUDBREAK PHARMA(02592.HK): IND Application for Novel Drug CBT-358 Completes Safety Review by US FDA
- Penghua CSI HK Equities Information Technology Integration ETF (159185) Rises Over 1% in Morning Session as Commercial Implementation of AI Drives Earnings Recovery in Hong Kong Tech
- Ascletis Pharma(01672.HK): Fixed-Dose Combination of GIPR Agonist ASC48 and GLP-1R Agonist ASC30 Selected for Clinical Development
- Weigao Group(01066.HK): Controlling Shareholder Adds Approximately 15.5988 Million H Shares, Cumulative Share Purchase Hits Around 30.55 Million Shares
